Santen Buys Asia, Europe Rights To Merck's Eye Drugs For $600 Million
This article was originally published in PharmAsia News
Executive Summary
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.
You may also be interested in...
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.